23andMe Holding Co - Ordinary Shares - Class A Aktie News

NEW YORK, NY / ACCESSWIRE / May 9, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

NEW YORK, NY / ACCESSWIRE / May 8, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

NEW YORK, NY / ACCESSWIRE / May 6, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

SAN FRANCISCO--(BUSINESS WIRE)--Potter Handy LLP, a leading consumer privacy law firm, today announced that it is representing nearly 5,000 individuals in California and Illinois impacted by the massive data breach at genetic testing company 23andMe (NASDAQ: ME). In October 2023, 23andMe revealed that an unauthorized third party had gained access to the accounts of approximately seven million c...

Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented

Matterport is being acquired by CoStar in a $1.7 billion cash and stock deal. The company not only has an excellent proprietary technology, but also a strong balance sheet.

Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.”